- Trial phase
- Phase 3
- Time to market
- If Phase 3 DAWN-303 succeeds, earliest potential regulatory submission would be around 2029-2030, given topline data expected in 2028.
- Why 4/10
- No hard binary catalyst is scheduled within the next ~12 months. The Phase 3 DAWN-303 topline readout is expected in 2028, and a Phase 3 adjuvant PDAC study is planned for 2027 (trial start, not data). Incyte is a multi-product company, so this single asset does not define the stock. Impact score reflects a mid-to-late stage investigational drug with impressive early data but no near-term approval or pivotal readout catalyst.
The ESMO 2026 Phase 1 data just landed (Oct 26) so this is the immediate catalyst cleared. The next major binary event is DAWN-303 Phase 3 topline data, expected no earlier than 2028 -- years out. In the nearer term, watch for Phase 3 adjuvant PDAC trial initiation (plans for 2027), the Genmab collaboration Phase 1/2 CRC study starting enrollment, and any competitive updates from Revolution Medicines' zoldonrasib program, which Incyte sees as its primary rival in the KRAS G12D space.
Price Chart
Executive Summary
INCB161734 (zecdarasib) is Incyte's investigational oral KRAS G12D inhibitor, a targeted therapy for KRAS G12D-mutated cancers -- most notably pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). On October 26, 2026 at ESMO, Incyte reported striking Phase 1 data: a 89% confirmed objective response rate and 90% six-month landmark progression-free survival when combined with chemo in first-line metastatic PDAC. A global Phase 3 trial (DAWN-303) in first-line PDAC is underway with topline data expected in 2028. The drug also showed a 36% response rate in later-line CRC with cetuximab, and a Phase 3 CRC study (DAWN-302) is being planned. Incyte is a diversified biopharma with approved products (Jakafi, Opzelura), so INCB161734 is one pipeline asset among several, but a potentially high-value one given the large addressable PDAC market.
How It Works
INCB161734 is a daily pill that targets a specific mutated form of a protein called KRAS (the G12D mutation). About 40% of pancreatic cancers and 15% of colorectal cancers carry this mutation, which acts as an "always-on" growth switch for cancer cells. The drug binds to the mutant KRAS protein and turns it off, blocking the cancer's growth signals. It is highly selective for the mutated form over normal KRAS (more than 80-fold selectivity) and is designed to work in both the active and inactive states of the protein.
Trial Status
Phase 1 monotherapy and combination dose-escalation/expansion data presented at ESMO 2026 (Oct 26). The Phase 3 DAWN-303 trial (NCT07522073) is actively recruiting: a randomized, double-blind study of chemotherapy with or without INCB161734 in previously untreated KRAS G12D-mutated metastatic PDAC. A Phase 3 study in adjuvant PDAC is planned for 2027. A Phase 3 CRC study (DAWN-302) is being planned. A Phase 1/2 collaboration with Genmab evaluating INCB161734 + petosemtamab + chemo in first-line KRAS G12D-mutated mCRC was announced Oct 24, 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 DAWN-303 topline data in first-line metastatic PDAC (expected 2028)
- Initiation of Phase 3 adjuvant PDAC study (planned 2027)
- Phase 3 CRC DAWN-302 study initiation in previously treated mCRC
- Phase 1/2 Genmab collaboration study enrollment data (INCB161734 + petosemtamab + chemo in first-line KRAS G12D mCRC)
- Competitive updates from Revolution Medicines' zoldonrasib program in PDAC and NSCLC
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INCYTE CORP 8-K INCY ·Originating report